Lansoprazole Capsule, Delayed Release
Product Images NDC 27241-020

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 27241-020). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lansoprazole_figure1 (Lansoprazole Figure1)

A line graph showing mean severity of day heartburn over days from start of treatment. It compares three groups: Placebo, Lansoprazole 15 mg QD, and Lansoprazole 30 mg QD, with severity scores from 0 (None) to 3 (Severe). Lansoprazole groups show a marked reduction in heartburn severity compared to placebo over approximately 55 days.*

FDA Label Image

Lansoprazole_figure2 (Lansoprazole Figure2)

A line graph showing mean severity of night heartburn over days from the start of treatment among patients. It compares placebo, lansoprazole 15 mg QD, and lansoprazole 30 mg QD, using a severity scale from 0 (none) to 3 (severe). The graph tracks changes from day -5 to day 60, illustrating the reduction in symptoms with lansoprazole at both dosages compared to placebo.*

FDA Label Image

Lansoprazole 15mg

Lansoprazole 15 mg delayed-release capsules label from Ajanta Pharma USA Inc. The label includes dosing information, a note that the package is child-resistant, storage instructions, and a 30-capsule count. It also features the NDC number 27241-019-03, pharmacist dispensing instructions, and bar code on the right side.*

FDA Label Image

Lansoprazole 30mg

Label for Lansoprazole Delayed-Release Capsules USP 30 mg, oral capsules. The package contains 30 capsules and is marketed by Ajanta Pharma USA Inc. The label includes instructions for pharmacists to dispense the Medication Guide and notes that the package is child-resistant. Storage instructions and usage cautions are also visible.*

FDA Label Image

Structure (Lansoprazole Str)

Chemical structure diagram of lansoprazole, showing its molecular components including a benzimidazole ring, sulfoxide group, and substituted pyridine ring with trifluoromethoxy side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.